As shown in Fig. S5D and S5E, both B4 and combination therapy groups effectively reduced the positivity rate of PLK1 in tumor tissues, indicating that PLKi effectively regulated its targets in both drug-resistant and non-drug-resistant tumors. This evidence concerns the gene PLK1 and neoplasm.